Estudo comparativo entre protocolos de ressecção e tratamento quimioterápico no câncer colorretal / Comparative study between resection protocols and chemotherapy treatment in colorectal cancer

Vinícius dos Santos Sá Rodrigues, Victoria Maria Jorge Freitas Colobó, Mariana Cavaliere Batista e Silva, Mariane de Carvalho Rasuck, Tiago Luis Machado Miranda, Deocárdio Cardoso Souto da Conceição, Giovana Castro de Paula Costa, Victor Hugo Ferrante Maia Athayde

Abstract


Objetivo: Abordar o manejo do câncer colorretal, discutindo  não só as indicações  dos principais procedimentos terapêuticos do CCR, mas também quando combiná-las.  Metodologia: Uma revisão integrativa desenvolvida a partir da seleção de ensaios clínicos publicados entre os anos de 2016 e 2021, disponíveis na base de dados do Pubmed. Os descritores utilizados foram: Cancer, colorectal OR Cancers, colorectal OR Carcinoma, colorectal OR Carcinomas, colorectal AND Chemotherapy AND Resection. Resultados:  Ainda que  alguns estudos demonstraram que a quimioterapia com FOLFIRIX foi favorável para a ressecção do câncer colorretal, outros atestam seu efeito negativo na ressecção de tumores  locais e metástases. O uso de probióticos está associado a uma redução significativa das complicações da quimioterapia. A quimioterapia hipertérmica intraperitoneal adjuvante (HIPEC) associada a quimioterapia sistêmica   demonstrou não superioridade em relação a apenas a quimioterapia.  A infusão intra-hepática não contribuiu para a melhora da sobrevida global. A fluorescência foi observada em todos pacientes submetidos à técnica de cirurgia guiada.  Conclusão: Ainda existem divergências com relação ao uso da terapia adjuvante, diferente da neoadjuvante que apresentou eficácia na maioria dos casos. Sugere-se a realização de novos estudos para sanar as divergências e observar a longo prazo os resultados, principalmente, das novas terapias.

 


Keywords


Neoplasias do Colo, Tratamento Farmacológico, Oncologia Cirúrgica, Revisão.

References


[Internet]. Gco.iarc.fr. 2021 [cited 19 April 2021]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf

Pellino G, Warren O, Mills S, Rasheed S, Tekkis P, Kontovounisios C. Comparison of Western and Asian Guidelines Concerning the Management of Colon Cancer. Diseases of the Colon & Rectum. 2018;61(2):250-259.

Ahmed M. Colon Cancer: A Clinician’s Perspective in 2019. Gastroenterology Research. 2020;13(1):1-10

A Rodriguez-Bigas M, Grothey A, K Tanabe K, M Goldberg R, Diane D. UpToDate [Internet]. Uptodate.com. 2021 [cited 27 April 2021]. Available from: https://www.uptodate.com/contents/overview-of-the-management-of-primary-colon-cancer.

Chan G, Chee C. Making sense of adjuvant chemotherapy in colorectal cancer. Journal of Gastrointestinal Oncology. 2019;10(6):1183-1192.

A Rodriguez-Bigas M. UpToDate [Internet]. Uptodate.com. 2021 [cited 27 April 2021]. Available from: https://www.uptodate.com/contents/surgical-resection-of-primary-colon-cancer#!

Yau T. Precision treatment in colorectal cancer: Now and the future. JGH Open. 2019;3(5):361-369.

Cremolini C, Antoniotti C, Lonardi S, et al. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA Oncol. 2018 Apr 1;4(4):529-536.

Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019 Dec 10;37(35):3401-3411.

Modest DP, Heinemann V, Folprecht G, et al. Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. Ann Surg Oncol. 2020 Jul;27(7):2389-2401.

Pietrantonio F, Di Bartolomeo M, Cotsoglou C, et al. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. Clin Colorectal Cancer. 2017 Sep;16(3):e191-e198.

Hurwitz HI, Tan BR, Reeves JA, et al. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist. 2019 Jul;24(7):921-932.

Shinozaki K, Yamada T, Nasu J, et al. A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). Int J Clin Oncol. 2021 Feb;26(2):399-408.

Iveson T, Boyd KA, Kerr RS, et al. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technol Assess. 2019 Dec;23(64):1-88.

Robles-Zurita J, Boyd KA, Briggs AH, et al. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. Br J Cancer. 2018 Nov;119(11):1332-1338.

Bajramagic S, Hodzic E, Mulabdic A, Holjan S, Smajlovic SV, Rovcanin A. Usage of Probiotics and its Clinical Significance at Surgically Treated Patients Sufferig from Colorectal Carcinoma. Med Arch. 2019 Oct;73(5):316-320.

Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):761-770.

Goéré D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020 Sep;21(9):1147-1154.

Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):256-266.

Hamaguchi T, Shimada Y, Mizusawa J, et al. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):47-56.

Aisu N, Yoshida Y, Komono A, Sakamoto R, Kojima D, Hasegawa S. Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study). Sci Rep. 2019 Nov 12;9(1):16568.

Konishi T, Shinozaki E, Murofushi K, et al. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. Ann Surg Oncol. 2019 Aug;26(8):2507-2513.

Kitano S, Inomata M, Mizusawa J, et al. Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):261-268.

Buisman FE, Grünhagen DJ, Homs MYV, et al. Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands. Ann Surg Oncol. 2019 Dec;26(13):4599-4607.

Kusano M, Honda M, Okabayashi K, et al. Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003. J Cancer Res Ther. 2017 Jan-Mar;13(1):84-90.

Zhang RX, Lin JZ, Lei J, et al. Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC). J Cancer Res Clin Oncol. 2017 Dec;143(12):2581-2593.

Park SY, Choi GS, Park JS, et al. Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Case-Control Study from a Single Center. Ann Surg Oncol. 2016 Jul;23(7):2266-73.

He WZ, Rong YM, Jiang C, et al. Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen. Chin J Cancer. 2016 Jun 29;35(1):58.

Biondo S, Frago R, Kreisler E, Espin-Basany E; Spanish CR4 Group. Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis. 2017 Jul;32(7):1085-1090.

Köhne CH, Karthaus M, Mineur L, et al. Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. Drugs R D. 2019 Sep;19(3):267-275.

Modest DP, Denecke T, Pratschke J, et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. Eur J Cancer. 2018 Jan;88:77-86.

Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016 Nov;17(11):1543-1557.

Mineur L, François E, Plassot C, et al. PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer. PLoS One. 2020 Dec 21;15(12):e0243997.

Tsuruta A, Yamashita K, Tanioka H, et al. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study. Drug Des Devel Ther. 2016 Nov 23;10:3827-3835.

Makhloufi S, Turpin A, El Amrani M, et al. Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. Ann Surg Oncol. 2020 Mar;27(3):877-885.

Rivera F, Valladares M, Gea S, López-Martínez N. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. J Med Econ. 2017 Jun;20(6):574-584.

Nagayama S, Hasegawa S, Hida K, et al. Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers. Int J Clin Oncol. 2017 Apr;22(2):316-323.

Harlaar NJ, Koller M, de Jongh SJ, et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. Lancet Gastroenterol Hepatol. 2016 Dec;1(4):283-290.

Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669-685.

Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial [published correction appears in Lancet Oncol. 2014 Jun;15(7):e253]. Lancet Oncol. 2014;15(6):601-611.

Kotzampassi K, Stavrou G, Damoraki G, et al. A Four-Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Double-Blind, Placebo-Controlled Study. World J Surg. 2015;39(11):2776-2783.

Mangell P, Thorlacius H, Syk I, et al. Lactobacillus plantarum 299v does not reduce enteric bacteria or bacterial translocation in patients undergoing colon resection. Dig Dis Sci. 2012;57(7):1915-1924.

García-Alfonso P, Muñoz Martín AJ, Ortega Morán L, et al. Oral drugs in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2021;13:17588359211009001. Published 2021 Apr 29.

Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(11):1543-1557.

Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol. 2017;18(3):357-370.

Iveson TJ, Kerr RS, Saunders MP, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2018;19(4):562-578.

Follette C, Liebscher S, Mouw T, Al-Kasspooles M. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) for Colorectal Cancer: Potential for Individualized Care, Review of Current Treatment Trends, Recent Advancements, and a Look into the Future. Current Colorectal Cancer Reports. 2019;15(1):36–44.

Yamamoto S, Inomata M, Katayama H, et al. Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. Ann Surg. 2014;260(1):23-30.

Kim CW, Baek JH, Choi GS, et al. The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial. Trials. 2016;17:34. Published 2016 Jan 19.

Verhoef C, de Wilt JH, Burger JW, Verheul HM, Koopman M. Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer. 2011;47 Suppl 3:S61-S66.




DOI: https://doi.org/10.34117/bjdv7n7-075

Refbacks

  • There are currently no refbacks.